News NHS broadens access to haemophilia A drug Hemlibra More people living with haemophilia A will be able to get access to Roche/Chugai's Hemlibra thanks to a commissioning agreement with NHS England.
News Roche's Hemlibra follow-up set for phase 3 in haemophilia A Roche has positive data with its follow-up to haemophilia A blockbuster Hemlibra, but a rival drug from Novo Nordisk is looming.
News Pfizer's weekly haemophilia drug backed for NHS use Some patients in England living with severe haemophilia B will soon be able to do away with need for regular infusions.
News Germany will reimburse haemophilia gene therapy Hemgenix Germany has agreed to reimburse CSL Behring's haemophilia B gene therapy Hemgenix with a 'unique' outcomes-based payment model.
News UK haemophilia A patients get once-weekly treatment option A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS.
News Pfizer drops Beqvez, leaving its gene therapy cupboard bare Pfizer has abandoned its haemophilia B treatment Beqvez in all world markets, saying weak demand made the business non-viable.
News FDA approves higher Wegovy dose via 4th priority voucher The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.